A5005609698- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Osteoarthritis Treatment and Mechanisms
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Inflammatory mediators and NSAID effects
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Proteoglycans and glycosaminoglycans research
- Systemic Sclerosis and Related Diseases
- Liver Diseases and Immunity
- Inflammatory Myopathies and Dermatomyositis
- Dermatology and Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Hepatitis C virus research
- Antiplatelet Therapy and Cardiovascular Diseases
- Immunotherapy and Immune Responses
- Urticaria and Related Conditions
- HER2/EGFR in Cancer Research
- Peripheral Neuropathies and Disorders
- Bone and Joint Diseases
- Acute Lymphoblastic Leukemia research
University of Utah
2014-2023
George E. Wahlen Department of VA Medical Center
2012-2022
VA San Diego Healthcare System
2020
VA Salt Lake City Healthcare System
2018-2019
Veterans Health Administration
2017
Center for Rheumatology
1999-2017
University of Utah Health Care
2012
United States Department of Veterans Affairs
1999-2010
University of Maryland, Baltimore
2008
Vrije Universiteit Amsterdam
2002
Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The multicenter, double-blind, placebo- celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy safety as a treatment for knee pain from osteoarthritis.We randomly assigned 1583 patients with symptomatic osteoarthritis receive 1500 mg of glucosamine daily, 1200 both sulfate, 200 celecoxib or placebo 24 weeks. Up 4000 acetaminophen daily was allowed rescue analgesia....
Abstract Objective To determine the safety and efficacy of etanercept in a multicenter, randomized, placebo‐controlled, double‐blind trial adults with moderate to severe active ankylosing spondylitis (AS). Methods Patients (n = 277) were treated either 25 mg 138) or placebo 139) subcutaneously twice weekly for 24 weeks. The primary outcome measures percentages patients achieving Assessments Ankylosing Spondylitis 20% response (ASAS20) at weeks 12 24. Other included percentage higher ASAS...
Abstract Objective . To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods Two hundred twenty‐one patients with PsA were recruited from 15 clinics, randomized (double‐blind) SSZ or placebo treatment, and followed up 36 weeks. Treatment response was based on joint pain/tenderness swelling scores physician patient global assessments. Results...
Objective To determine if the peripheral articular manifestations of seronegative spondylarthropathies (SNSA) respond differently than axial to treatment with sulfasalazine (SSZ). Methods This is a reanalysis previously reported series randomized, double-blind, placebo-controlled, multicenter trials comparing effects SSZ, 2,000 mg/day, and placebo on ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive (ReA; Reiter's syndrome). Patients were classified as responders basis meeting...
Abstract Objective. To compare the relative safety and efficacy of naproxen acetaminophen in treatment osteoarthritis (OA) knee. The major outcome measures were radiographic progression withdrawal from trial due to lack efficacy. Methods. One hundred seventy‐eight patients with OA knee enrolled a 2‐year prospective, controlled, double‐blind multicenter randomly assigned receive (ACT) or (NPX) treatment. Results. After 6 weeks treatment, modest improvement pain on motion physician's global...
Abstract Objective Osteoarthritis (OA) of the knee causes significant morbidity and current medical treatment is limited to symptom relief, while therapies able slow structural damage remain elusive. This study was undertaken evaluate effect glucosamine chondroitin sulfate (CS), alone or in combination, as well celecoxib placebo on progressive loss joint space width (JSW) patients with OA. Methods A 24‐month, double‐blind, placebo‐controlled study, conducted at 9 sites United States part...
Knee osteoarthritis (OA) is a major cause of pain and functional limitation in older adults, yet longer-term studies medical treatment OA are limited.
A number of non-HLA loci that have shown evidence (P < 0.05) for linkage with rheumatoid arthritis (RA) been previously identified. The present study attempts to confirm these findings.We performed a second genome-wide screen 256 new multicase RA families recruited from across the United States by North American Rheumatoid Arthritis Consortium. Affected sibling pair analysis on data set was using SIBPAL. We subsequently combined our first and sets in an attempt enhance linkages larger sample...
Abstract Objective . To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment active ankylosing spondylitis (AS) that not controlled with nonsteroidal antiinflammatory drug therapy. Methods Two hundred sixty‐four patients AS were recruited from 15 clinics, randomized (double‐blind) to SSZ or placebo treatment, and followed up 36 weeks. Treatment response was based on morning stiffness, back pain, physician patient global assessments. Results While...
Abstract Objective. To compare the relative safety and efficacy of auranofin (AUR), metbotrexate (MTX), combination both in treatment active rheumatoid arthritis (RA). Methods. Three hundred thirty‐five patients with RA were entered into a 48‐week, prospective, controlled, double‐blind, multicenter trial randomly assigned to 1 3 groups. Results. Two eleven completed trial. No remissions seen, there no statistically significant differences among groups clinical or laboratory variables...
<h3>Objective:</h3> Evaluate long-term safety and efficacy of etanercept treatment in patients with ankylosing spondylitis (AS). <h3>Methods:</h3> Patients AS who previously participated a randomised controlled trial (RCT) were eligible to enrol 168-week open-label extension (OLE). Safety end points included rates adverse events (AE), serious (SAE), infections, infections death. Efficacy Assessment Ankylosing Spondylitis (ASAS20) response, ASAS 5/6 response partial remission rates....
Abstract Objective . To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective in the treatment reactive arthritis (ReA) that has been unresponsive to nonsteroidal antiinflammatory drug (NSAID) therapy. Methods One hundred thirty‐four patients with ReA who had failed respond NSAIDs were recruited from 19 clinics, randomized (double‐blind) receive either SSZ or placebo, and followed up for 36 weeks. The definition response was based on joint pain/tenderness swelling...
Abstract One hundred eighty‐six patients with active rheumatoid arthritis were evaluated in a double‐blind, randomized study that compared treatment sulfasalazine (SSZ) (2 gm/day), gold sodium thiomalate (GST) (50 mg/week), and placebo (PBO). The 37—week course of therapy was completed by 109 patients. While marked improvement seen all 3 groups, the only statistically significant differences between SSZ or GST PBO decreased erythrocyte sedimentation rate increased grip strength right hand....